Abstract
TNF–related apoptosis–inducing ligand has selective antitumor activity in mice without causing toxic side effects and may have potential as a cancer therapeutic (157–163).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization
Cell Death & Disease Open Access 04 February 2019
-
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Journal for ImmunoTherapy of Cancer Open Access 18 August 2015
-
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death
Molecular Cancer Open Access 17 April 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coley, W.B. Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199–220 (1891).
Vassalli, P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10, 411–452 (1992).
Walczak, H. et al. Tumoricidal activity of TRAIL in vivo. Nature Med. 5, 157–163 (1999).
Smith, C.A., Farrah, T. & Goodwin, R.G. The TNF–receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76, 959–962 (1994).
Ashkenazi, A. & Dixit, V.M. Death receptors: Signaling and modulation. Science 281, 1305–1308 (1998).
Schneider, P. et al. Conversion of membrane–bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1–9 (1998).
Wiley, S.R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682 (1995).
Griffith, T.S. & Lynch, D.H. TRAIL: A molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10, 559–563 (1998).
Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190–195 (1997).
Pan, G. et al. An antagonist decoy receptor and a death domain–containing receptor for TRAIL. Science 277, 815– 818 (1997).
Sheridan, J.P. et al. Control of TRAIL–induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821 (1997).
Wu, G.S. et al. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene [letter]. Nature Genet. 17, 141–143 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
French, L., Tschopp, J. The TRAIL to selective tumor death. Nat Med 5, 146–147 (1999). https://doi.org/10.1038/5505
Issue Date:
DOI: https://doi.org/10.1038/5505
This article is cited by
-
Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer
Apoptosis (2022)
-
Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization
Cell Death & Disease (2019)
-
Diethylamino-curcumin mimic with trizolyl benzene enhances TRAIL-mediated cell death on human glioblastoma cells
Molecular & Cellular Toxicology (2018)
-
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Journal for ImmunoTherapy of Cancer (2015)
-
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors
Cancer Immunology, Immunotherapy (2015)